Walleye Capital’s Ventyx Biosciences VTYX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-4,080
| Closed | -$36.8K | – | 5041 |
|
|
2025
Q4 | $36.8K | Sell |
4,080
-181,385
| -98% | -$1.36M | ﹤0.01% | 4150 |
|
|
2025
Q3 | $577K | Sell |
185,465
-236,629
| -56% | -$627K | ﹤0.01% | 2498 |
|
|
2025
Q2 | $903K | Sell |
422,094
-82,151
| -16% | -$133K | ﹤0.01% | 2135 |
|
|
2025
Q1 | $580K | Buy |
504,245
+26,457
| +6% | +$45.4K | ﹤0.01% | 2428 |
|
|
2024
Q4 | $1.05M | Buy |
477,788
+87,686
| +22% | +$199K | ﹤0.01% | 2344 |
|
|
2024
Q3 | $850K | Sell |
390,102
-120,730
| -24% | -$278K | ﹤0.01% | 2814 |
|
|
2024
Q2 | $1.18M | Buy |
510,832
+194,854
| +62% | +$810K | ﹤0.01% | 2663 |
|
|
2024
Q1 | $1.74M | Buy |
315,978
+258,483
| +450% | +$1.18M | ﹤0.01% | 2097 |
|
|
2023
Q4 | $142K | Buy |
+57,495
| New | +$546K | ﹤0.01% | 3874 |
|
|
2023
Q2 | – | Sell |
-21,857
| Closed | -$732K | – | 4930 |
|
|
2023
Q1 | $732K | Sell |
21,857
-102,935
| -82% | -$4M | 0.01% | 1385 |
|
|
2022
Q4 | $4.09M | Buy |
124,792
+98,392
| +373% | +$2.91M | 0.07% | 315 |
|
|
2022
Q3 | $922K | Buy |
+26,400
| New | +$585K | 0.02% | 1040 |
|
Other funds holding VTYX
Walleye Capital's VTYX Position: Q1 2026 in Review
Walleye Capital sold out of Ventyx Biosciences (VTYX) in Q1 2026, closing a stake of 4,080 shares — an estimated $36.8K sold.
Walleye Capital first reported a position in VTYX in Q3 2022 and held it in 12 quarters. The position peaked at $4.09M in Q4 2022. 1 fund tracked by Wall St. Rank holds VTYX as of Q1 2026.
- Walleye Capital reported no remaining Ventyx Biosciences position as of Q1 2026 after selling out during the quarter.
- Walleye Capital sold 4,080 Ventyx Biosciences shares in Q1 2026, an estimated $36.8K.
- Walleye Capital first reported a position in Ventyx Biosciences in Q3 2022 and held it in 12 quarters.
- Walleye Capital's Ventyx Biosciences position peaked at $4.09M in Q4 2022.
- 1 fund tracked by Wall St. Rank held Ventyx Biosciences as of Q1 2026.
Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.